Strides Pharma Reports Strong Q2 as Net Profit Surges 82%
Strides Pharma Science posted a sharp improvement in quarterly earnings, reporting that net profit rose 82% year-on-year to ₹131.5 crore in Q2 FY25, supported by robust U.S. business performance and margin expansion. Revenue grew 15% to ₹1,193 crore, driven by continued growth in regulated markets and improved product mix. The U.S. segment recorded 22% growth, supported by new launches and higher market share in key therapy areas, while the institutional business also contributed to revenue gains. The company reported an EBITDA margin of 20.3%, compared with 16.7% a year earlier, reflecting more favourable pricing and operational efficiencies. Management said the company remained focused on expanding its U.S. pipeline, strengthening its branded portfolio across emerging markets and scaling high-margin businesses. Strides reiterated confidence in sustaining double-digit growth, supported by steady launches and the monetisation of niche products in the quarters ahead.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Retatrutide/Tirzepatide/Cagri/Ghk-Cu 99% White Raw Power High Quality 2381089-83-2 Weight Loss Peptide
$178.7/G FOB
2026-07-16
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
McKinsey Pays to Close a Purdue Liability Chapter
Recommend Reading
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
-
JB Pharma Q1 Net Profit Surges 14 Percent to ₹202 Crore Revenue Hits ₹1094 Crore with 30 Percent EBITDA Margin
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
-
Construction Starts Decline; Isooctanol Prices Fluctuate and Fall This Week
-
This Week's Activated Carbon Prices Rise (11.10-11.14)
-
Costs Decline as Phthalic Anhydride Prices Fluctuate and Fall This Week
-
This Round of Refined Oil Retail Price Adjustment Faces Another Suspension
-
Both Supply and Demand Weak, PCs in Volatile Operation Mid-May